About Apogee Therapeutics, Inc. - Common Stock (APGE)
Apogee Therapeutics, Inc. is a biotechnology company focused on developing innovative therapeutic solutions for a range of diseases by harnessing the power of immune system modulation. The company specializes in creating treatments that aim to effectively address conditions that involve dysregulated immune responses. Through its advanced research and development efforts, Apogee Therapeutics is dedicated to improving the lives of patients by providing targeted therapies that can enhance treatment outcomes and reduce the burden of chronic illnesses. Read More
SAN FRANCISCO and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 10:30 a.m. E.T.
Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53%
SAN FRANCISCO and BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will present at the Bank of America Health Care Conference on Tuesday, May 13, 2025, at 1:40 p.m. P.T. / 4:40 p.m. E.T.
Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent.
Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025
Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, exceeded trial objectives and demonstrated an approximately 60-day half-life
SAN FRANCISCO and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE) today announced that members of management will participate at the following investor conferences.
SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 1:00 p.m. E.T.
